الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>(S)-Sunvozertinib

(S)-Sunvozertinib (Synonyms: (S)-DZD9008)

رقم الكتالوجGC63797

(S) -Sunvozertinib ((S) -DZD9008) ، S-enantiomer من Sunvozertinib ، يُظهر نشاطًا مثبطًا ضد إدخال EGFR exon 20 NPH و ASV ، طفرة EGFR L858R / T790M وإدخال Her2 exon20 YVMA (IC50 = 51.2 نانومتر ، 51.9 نانومتر و 1 نانومتر و 21.2 نانومتر على التوالي)(S) -Sunvozertinib يثبط BTK أيضًا

Products are for research use only. Not for human use. We do not sell to patients.

(S)-Sunvozertinib التركيب الكيميائي

Cas No.: 2370013-49-1

الحجم السعر المخزون الكميّة
5 mg
122٫00
متوفر
10 mg
194٫00
متوفر
25 mg
389٫00
متوفر
50 mg
619٫00
متوفر
100 mg
929٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK[1].

(S)-Sunvozertinib shows proliferation inhibition of Ba/F3 EGFR NPH ins (GI50=139.7 nM), Ba/F3 FGFR ASV ins (155.7 nM), NCI-HI975 EGFRL858R/T790M (24.4), Her2 YVMA ins (827 nM) and WT EGFR (84.8 nM)[1].(S)-Sunvozertinib shows proliferation inhibition of BTK WT cells (OCI-LY-10, TMD-8, Ri-1and DB, with GI50 ranging from 13.7-48 nM)[1].

[1]. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.

مراجعات

Review for (S)-Sunvozertinib

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (S)-Sunvozertinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.